ATE486087T1 - Fgf-5-bindende und geträgerte peptide - Google Patents

Fgf-5-bindende und geträgerte peptide

Info

Publication number
ATE486087T1
ATE486087T1 AT04818640T AT04818640T ATE486087T1 AT E486087 T1 ATE486087 T1 AT E486087T1 AT 04818640 T AT04818640 T AT 04818640T AT 04818640 T AT04818640 T AT 04818640T AT E486087 T1 ATE486087 T1 AT E486087T1
Authority
AT
Austria
Prior art keywords
peptides
supported
preferred embodiments
fgf
binding
Prior art date
Application number
AT04818640T
Other languages
English (en)
Inventor
Anthony G Day
David A Estell
Christopher J Murray
Scott D Power
Beverly R Turnquest
Original Assignee
Danisco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco Us Inc filed Critical Danisco Us Inc
Application granted granted Critical
Publication of ATE486087T1 publication Critical patent/ATE486087T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
AT04818640T 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide ATE486087T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51815403P 2003-11-06 2003-11-06
US52040303P 2003-11-13 2003-11-13
US53120703P 2003-12-19 2003-12-19
US53095403P 2003-12-19 2003-12-19
US53118903P 2003-12-19 2003-12-19
PCT/US2004/036980 WO2005047314A2 (en) 2003-11-06 2004-11-06 Fgf-beta binding and supported peptides

Publications (1)

Publication Number Publication Date
ATE486087T1 true ATE486087T1 (de) 2010-11-15

Family

ID=34596198

Family Applications (4)

Application Number Title Priority Date Filing Date
AT04800809T ATE513917T1 (de) 2003-11-06 2004-11-06 Bakterielle expression von proteaseinhibitoren und varianten davon
AT04810431T ATE530560T1 (de) 2003-11-06 2004-11-06 Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
AT04818640T ATE486087T1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide
AT04810432T ATE482972T1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT04800809T ATE513917T1 (de) 2003-11-06 2004-11-06 Bakterielle expression von proteaseinhibitoren und varianten davon
AT04810431T ATE530560T1 (de) 2003-11-06 2004-11-06 Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04810432T ATE482972T1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide

Country Status (9)

Country Link
US (8) US20080113917A1 (de)
EP (4) EP1692158B1 (de)
JP (2) JP4843497B2 (de)
AT (4) ATE513917T1 (de)
CA (1) CA2544820C (de)
DE (2) DE602004029812D1 (de)
DK (2) DK1680507T3 (de)
ES (1) ES2375360T3 (de)
WO (4) WO2005046709A2 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834554B2 (ja) * 2003-11-06 2011-12-14 ジェネンコー・インターナショナル・インク 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現
ATE513917T1 (de) * 2003-11-06 2011-07-15 Genencor Int Bakterielle expression von proteaseinhibitoren und varianten davon
DK1800136T3 (da) * 2004-10-15 2012-03-26 Danisco Us Inc Kompetitiv differentiel screening
CN101278051B (zh) * 2005-05-05 2011-10-05 金克克国际有限公司 个人护理组合物及其使用方法
US8063019B2 (en) 2005-06-10 2011-11-22 Medical Research Council Scaffold polypeptides for heterologous peptide display
WO2007009018A2 (en) * 2005-07-13 2007-01-18 Amgen Mountain View Inc. Il-6 binding proteins
GB0601684D0 (en) * 2006-01-27 2006-03-08 Reckitt Benckiser Uk Ltd Composition, process for preparation and method of use
WO2007092465A2 (en) * 2006-02-07 2007-08-16 Dyao Pharmaceutical Corporation Topical delivery compositions
EP2641608B1 (de) * 2006-09-16 2015-03-04 SOY Labs LLC Pharmazeutische Zusammensetzung enthaltend Lunasinangereicherten Samenextract und Sojamehl
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
EP2094842B1 (de) 2006-12-18 2012-06-13 Danisco US Inc. Neue laccasen, zusammensetzungen und verwendungsverfahren dafür
WO2008088493A2 (en) 2006-12-21 2008-07-24 Danisco Us, Inc., Genencor Division Compositions and uses for an alpha-amylase polypeptide of bacillus species 195
BRPI0812446A2 (pt) * 2007-06-06 2014-10-14 Danisco Us Inc Genecor Division Métodos para aperfeiçoamento de propriedades de proteína múltiplas
US20090048136A1 (en) * 2007-08-15 2009-02-19 Mcdonald Hugh C Kappa-carrageenase and kappa-carrageenase-containing compositions
WO2009058518A1 (en) * 2007-10-31 2009-05-07 Danisco Us Inc., Genencor Division Use and production of neutral metallproteases in a serine protease-free background
MX2010004325A (es) * 2007-11-01 2010-05-20 Danisco Us Inc Secuencias de señal y chaperones co-expresados para mejorar produccion de proteinas en una celula hospedera.
GB0722332D0 (en) * 2007-11-14 2007-12-27 Reckitt Benckiser Uk Ltd Personal care article
CN101952308A (zh) * 2008-01-29 2011-01-19 丹尼斯科美国公司 链霉菌枯草杆菌蛋白酶抑制剂(ssi)蛋白在芽孢杆菌属和链霉菌属物种中的表达
US8236545B2 (en) 2008-02-04 2012-08-07 Danisco Us Inc., Genencor Division TS23 alpha-amylase variants with altered properties
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
RU2509776C2 (ru) * 2008-10-15 2014-03-20 ДАНИСКО ЮЭс ИНК. МОДИФИЦИРОВАННЫЕ ВАРИАНТЫ ИНГИБИТОРОВ ПРОТЕАЗ Bowman Birk
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
CN102341495A (zh) 2009-03-10 2012-02-01 丹尼斯科美国公司 巨大芽孢杆菌菌株DSM90相关的α-淀粉酶及其使用方法
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
CN102388131B (zh) 2009-04-08 2014-04-30 丹尼斯科美国公司 盐单胞菌属菌株WDG195相关α-淀粉酶及其使用方法
CN105238801A (zh) 2009-04-24 2016-01-13 丹尼斯科美国公司 具有修饰的原区的蛋白酶
CA2760554A1 (en) * 2009-05-01 2010-11-04 Signal Investment And Management Co. Moisturizing antimicrobial composition
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
GB0921001D0 (en) * 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
BR112012014082B1 (pt) 2009-12-09 2020-12-15 Danisco Us Inc variante de protease isolada e seu método de produção, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante, composição e método para limpeza de um item ou de uma superfície em necessidade de limpeza
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
US20130023649A1 (en) * 2009-12-30 2013-01-24 Karsten Keller Method for Recovering Kunitz-Trypsin Inhibitor Proteins from a Soy Processing Stream
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
WO2011123061A1 (en) * 2010-03-31 2011-10-06 Agency For Science, Technology And Research Amphiphilic linear peptide/peptoid and hydrogel comprising the same
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
US20110281327A1 (en) 2010-04-15 2011-11-17 Danisco Us Inc. Compositions And Methods Comprising Variant Proteases
CN108410585A (zh) 2010-05-06 2018-08-17 宝洁公司 具有蛋白酶变体的消费品
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
JP5933688B2 (ja) 2011-05-05 2016-06-15 ザ プロクター アンド ギャンブル カンパニー セリンプロテアーゼ変異体を含む組成物及び方法
CN103764823B (zh) 2011-05-05 2018-05-11 丹尼斯科美国公司 包含丝氨酸蛋白酶变体的组合物和方法
EP2751263A1 (de) 2011-08-31 2014-07-09 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
CN104024407A (zh) 2011-12-22 2014-09-03 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
US9120841B2 (en) 2012-09-28 2015-09-01 Agency For Science, Technology And Research Amphiphilic linear peptidepeptoid and hydrogel comprising the same
AU2013328953A1 (en) 2012-10-12 2015-03-26 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
AU2013337255A1 (en) 2012-11-05 2015-04-02 Danisco Us Inc. Compositions and methods comprising thermolysin protease variants
US20150344858A1 (en) 2012-12-19 2015-12-03 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014194117A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
WO2014194054A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
US20160160202A1 (en) 2013-05-29 2016-06-09 Danisco Us Inc. Novel metalloproteases
EP4159854A1 (de) 2013-05-29 2023-04-05 Danisco US Inc Neuartige metalloproteasen
EP3022299B1 (de) 2013-07-19 2020-03-18 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
JP6678108B2 (ja) 2013-09-12 2020-04-08 ダニスコ・ユーエス・インク Ｌｇ１２−系統群プロテアーゼ変異体を含む組成物及び方法
JP2016537965A (ja) * 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド Ｎｓｐ４阻害剤及び使用方法
CN105813695A (zh) 2013-11-01 2016-07-27 斯弗尤姆生物制药有限公司 用于透皮递送治疗剂和美容剂的包含体
WO2015089447A1 (en) 2013-12-13 2015-06-18 Danisco Us Inc. Serine proteases of the bacillus gibsonii-clade
EP3514230B1 (de) 2013-12-13 2021-09-22 Danisco US Inc. Serinproteasen aus einer bacillus-spezies
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
JP6585698B2 (ja) 2014-03-21 2019-10-02 ダニスコ・ユーエス・インク バチルス（Ｂａｃｉｌｌｕｓ）種のセリンプロテアーゼ
EP3207129B1 (de) 2014-10-17 2019-11-20 Danisco US Inc. Serinproteasen aus einer bacillus-spezies
US20180010074A1 (en) 2014-10-27 2018-01-11 Danisco Us Inc. Serine proteases of bacillus species
WO2016069552A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
EP3957729A1 (de) 2014-10-27 2022-02-23 Danisco US Inc. Serinproteasen
EP3212781B1 (de) 2014-10-27 2019-09-18 Danisco US Inc. Serinproteasen
WO2016069544A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
US20180216090A1 (en) 2015-03-12 2018-08-02 Danisco Us Inc. Compositions and methods comprising lg12-clade protease variants
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3294884B1 (de) 2015-05-13 2021-01-27 Danisco US Inc. Aprl-clade-protease-varianten and verwendungen davon
CA2989667A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Proteases with modified propeptide regions
EP4234693A3 (de) 2015-06-17 2023-11-01 Danisco US Inc Bacillus-gibboni-clade-serin-proteasen
CN107022432A (zh) * 2016-01-29 2017-08-08 高露洁-棕榄公司 清洁组合物
BR112018072586A2 (pt) 2016-05-05 2019-02-19 Danisco Us Inc variantes de protease e usos das mesmas
US11661567B2 (en) 2016-05-31 2023-05-30 Danisco Us Inc. Protease variants and uses thereof
MX2018015559A (es) 2016-06-17 2019-06-06 Danisco Us Inc Variantes de proteasa y sus usos.
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP4424805A3 (de) 2016-12-21 2024-11-20 Danisco Us Inc Bacillus gibsonii-clade-serinproteasen
US20200392477A1 (en) 2016-12-21 2020-12-17 Danisco Us Inc. Protease variants and uses thereof
US11298391B1 (en) * 2017-04-27 2022-04-12 Lorenol Laboratories, Inc. Topical skin health improvement compositions and administrations thereof
WO2019108599A1 (en) 2017-11-29 2019-06-06 Danisco Us Inc Subtilisin variants having improved stability
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
EP3799601A1 (de) 2018-06-19 2021-04-07 Danisco US Inc. Subtilisinvarianten
US20240279627A1 (en) 2018-08-30 2024-08-22 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
EP3875591A4 (de) * 2018-10-31 2022-09-21 Qingdao Vland Biotech Group Co. Ltd. Verfahren zur herstellung eines waschenzyms mit proteaseresistenz
US12509672B2 (en) 2018-11-28 2025-12-30 Danisco Us Inc. Subtilisin variants having improved stability
CN114174504A (zh) 2019-05-24 2022-03-11 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
CN112062828B (zh) * 2019-06-10 2022-04-29 温州医科大学 Fgf-5多肽抑制剂及其生发应用
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
EP4090727A1 (de) 2020-01-13 2022-11-23 Danisco US Inc. Zusammensetzungen mit einer lipolytischen enzymvariante und verfahren zur verwendung davon
EP3872088A1 (de) * 2020-02-28 2021-09-01 Alganelle Verwendung von aprotinin als träger zum herstellen eines rekombinanten proteins, polypeptides oder peptids in algen
US20240034960A1 (en) 2020-08-27 2024-02-01 Danisco Us Inc Enzymes and enzyme compositions for cleaning
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
US20240294888A1 (en) 2021-06-30 2024-09-05 Danisco Us Inc. Variant enzymes and uses thereof
EP4396320A2 (de) 2021-09-03 2024-07-10 Danisco US Inc. Waschmittelzusammensetzungen zum reinigen
WO2023114794A1 (en) 2021-12-16 2023-06-22 The Procter & Gamble Company Fabric and home care composition comprising a protease
CN118369414A (zh) 2021-12-16 2024-07-19 宝洁公司 包含蛋白酶的自动盘碟洗涤组合物
CN118679252A (zh) 2021-12-16 2024-09-20 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
EP4448750A2 (de) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisinvarianten und verwendungen davon
US20250051748A1 (en) 2021-12-16 2025-02-13 Danisco Us Inc. Subtilisin variants and methods of use
CN118974227A (zh) 2022-03-01 2024-11-15 丹尼斯科美国公司 用于清洁的酶和酶组合物
EP4581138A1 (de) 2022-09-02 2025-07-09 Danisco US Inc. Subtilisinvarianten und damit in zusammenhang stehende verfahren
CA3265943A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. DETERGENT COMPOSITIONS AND ASSOCIATED PROCESSES
EP4615968A1 (de) 2022-11-09 2025-09-17 Danisco US Inc. Subtilisinvarianten und verfahren zur verwendung
US20240263162A1 (en) 2023-02-01 2024-08-08 The Procter & Gamble Company Detergent compositions containing enzymes
EP4658776A1 (de) 2023-02-01 2025-12-10 Danisco US Inc. Subtilisinvarianten und verfahren zur verwendung
CN120712348A (zh) 2023-03-06 2025-09-26 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
WO2025071996A1 (en) 2023-09-28 2025-04-03 Danisco Us Inc. Variant cutinase enzymes with improved solubility and uses thereof
WO2025085351A1 (en) 2023-10-20 2025-04-24 Danisco Us Inc. Subtilisin variants and methods of use
WO2026024921A1 (en) 2024-07-25 2026-01-29 The Procter & Gamble Company Detergent composition comprising a subtilisin variant and methods of use
WO2026050315A1 (en) 2024-08-29 2026-03-05 Danisco Us Inc. Subtilisin variants and methods of use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
DE2437090A1 (de) * 1974-08-01 1976-02-19 Hoechst Ag Reinigungsmittel
JPS51125468A (en) * 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
US4152416A (en) * 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FI69503C (fi) * 1984-03-13 1986-02-10 Neste Oy Ytbelagd bergsbehaollare eller tunnel
US5411873A (en) * 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4999186A (en) * 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4937370A (en) * 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US5322770A (en) * 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1988002025A1 (en) * 1986-09-17 1988-03-24 Sri International Expression vectors for bacilli
US5087372A (en) * 1989-03-24 1992-02-11 Asahi Kasei Kogyo Kabushiki Kaisha Method for removing heavy metal ions from contaminated water and a porous membrane usable therefor
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073371A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5429950A (en) * 1992-03-30 1995-07-04 Genencor International, Inc. Heterologous gene expression in bacillus subtilis: fusion approach
GB9415421D0 (en) 1994-07-30 1994-09-21 Procter & Gamble Cosmetic compositions and processes for manufacture thereof
AU709850B2 (en) 1994-11-28 1999-09-09 Procter & Gamble Company, The Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents
CA2246622A1 (en) * 1996-03-12 1997-09-18 Genencor International, Inc. Alkaline cellulase and method of producing same
JP2001519765A (ja) * 1996-04-18 2001-10-23 ザ ジェネラル ホスピタル コーポレイション 上皮―間充織相互作用の調節
US5827508A (en) * 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
KR20000057166A (ko) 1996-11-22 2000-09-15 데이비드 엠 모이어 미용 조성물
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
SK692001A3 (en) * 1998-07-20 2001-12-03 M & E Biotech As Novel methods for the identification of ligand and target biomolecules
US5989528A (en) 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
US5935556A (en) * 1998-07-30 1999-08-10 The Procter & Gamble Company Sunscreen compositions
JP3855042B2 (ja) * 1998-09-22 2006-12-06 独立行政法人産業技術総合研究所 毛髪の鑑別法
US5968485A (en) * 1998-10-16 1999-10-19 The Procter & Gamble Company UV protection compositions
US5972316A (en) * 1998-10-16 1999-10-26 The Procter & Gamble Company UV protection compositions
WO2000024371A1 (en) 1998-10-23 2000-05-04 The Procter & Gamble Company Skin care compositions
GB9825854D0 (en) * 1998-11-25 1999-01-20 Univ Bristol Peptide
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
AU5056501A (en) * 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
DK1360500T3 (da) * 2000-04-14 2010-05-25 Genencor Int Fremgangsmåde til selektiv målretning
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6822082B2 (en) * 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
BR0116138A (pt) * 2000-12-13 2003-09-23 Borean Pharma As Bibliotecas combinatóriais de proteìnas tendo a estrutura de andaime de domìnios tipo lectina tipo c
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2002094867A2 (fr) * 2001-02-07 2002-11-28 Institut Pasteur Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
MXPA05008535A (es) * 2003-02-11 2006-03-08 Pasteur Institut Identificacion y caracterizacion de racemasas, definicion de firmas proteinicas, y una prueba para examinar aminoacido d para seleccionar moleculas capaces de inhibir la actividad de racemasa, especialmente racemasa de prolina.
ATE513917T1 (de) * 2003-11-06 2011-07-15 Genencor Int Bakterielle expression von proteaseinhibitoren und varianten davon
JP4834554B2 (ja) * 2003-11-06 2011-12-14 ジェネンコー・インターナショナル・インク 糸状菌におけるプロテアーゼ抑制剤及びその変異体の発現
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US7803902B2 (en) * 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors

Also Published As

Publication number Publication date
DE602004029393D1 (de) 2010-11-11
US20080113917A1 (en) 2008-05-15
WO2005046710A3 (en) 2005-11-24
US7413877B2 (en) 2008-08-19
ATE513917T1 (de) 2011-07-15
CA2544820A1 (en) 2005-05-26
ATE482972T1 (de) 2010-10-15
WO2005046710A2 (en) 2005-05-26
EP1692159A2 (de) 2006-08-23
DK1680507T3 (da) 2011-10-10
JP2008500805A (ja) 2008-01-17
WO2005047511A2 (en) 2005-05-26
EP1692158B1 (de) 2011-10-26
EP1692160B1 (de) 2010-10-27
US20090111160A1 (en) 2009-04-30
EP1692160A2 (de) 2006-08-23
WO2005046709A2 (en) 2005-05-26
WO2005047511A3 (en) 2005-11-24
EP1692158A2 (de) 2006-08-23
DE602004029812D1 (de) 2010-12-09
JP2012024091A (ja) 2012-02-09
US20130065829A1 (en) 2013-03-14
WO2005046709A3 (en) 2005-11-24
US20050202535A1 (en) 2005-09-15
US7524816B2 (en) 2009-04-28
ES2375360T3 (es) 2012-02-29
ATE530560T1 (de) 2011-11-15
JP4843497B2 (ja) 2011-12-21
JP5728329B2 (ja) 2015-06-03
WO2005047314A3 (en) 2006-04-20
US7696173B2 (en) 2010-04-13
US20050203026A1 (en) 2005-09-15
US20110230405A1 (en) 2011-09-22
WO2005047314A2 (en) 2005-05-26
EP1680507A2 (de) 2006-07-19
US20080269139A1 (en) 2008-10-30
US7485618B2 (en) 2009-02-03
US20050238607A1 (en) 2005-10-27
EP1692159B1 (de) 2010-09-29
DK1692158T3 (da) 2012-02-06
EP1680507B1 (de) 2011-06-22
CA2544820C (en) 2014-02-18

Similar Documents

Publication Publication Date Title
ATE486087T1 (de) Fgf-5-bindende und geträgerte peptide
WO2006121610A3 (en) Personal care compositions and methods for their use
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
BRPI0519430A2 (pt) hormânio do crescimento humano modificado
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
WO2003093305A3 (en) Teneurin c-terminal associated peptides (tcap) and uses thereof
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus
ATE528392T1 (de) Neues protein und dessen dns
SE0202608D0 (sv) New sequences

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties